Form 4: Theravance Biopharma Exec Sells Shares for Tax
Insider Transaction
Theravance Biopharma's SVP, General Counsel, and Secretary, Brett A. Grimaud, disposed of shares to cover tax obligations from vested restricted stock units.
Summary
- Brett A. Grimaud, SVP, General Counsel, and Secretary of Theravance Biopharma, Inc. (TBPH), reported a disposition of ordinary shares.
- On November 20, 2025, Mr. Grimaud disposed of 19,024 ordinary shares at a price of $17.9 per share.
- The disposition was a withholding of shares by the issuer to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
- This transaction was not an open market sale but a direct transaction with the issuer.
- Following this transaction, Mr. Grimaud beneficially owns 355,282 ordinary shares.
Sentiment
Score: 5
Explanation: The filing reports a routine insider transaction for tax purposes, which is neutral in sentiment and does not indicate any positive or negative operational or financial developments for the company.
Industry Context
This filing represents a routine insider transaction common in the biotechnology and pharmaceutical industries, where executive compensation often includes equity awards like restricted stock units. The disposition for tax withholding is a standard mechanism for executives to cover tax liabilities upon the vesting of such awards.
Related Party Transactions
- The share withholding transaction was conducted directly with the issuer, Theravance Biopharma, Inc., to satisfy tax obligations, rather than through an open market sale.
Stakeholder Impact
- Shareholders: Minimal impact as this is a routine, non-open market transaction for tax purposes and does not reflect a change in management's confidence or company fundamentals.
- Employees: No direct impact on the broader employee base, as this relates to executive equity compensation.
Key Dates
| Date | Description |
|---|---|
| 11/20/2025 | Date of transaction (disposition of shares) |
| 11/24/2025 | Date the Form 4 was signed and filed |
Keywords
Theravance Biopharma, TBPH, Form 4, Insider Transaction, Share Disposition, Tax Withholding, Restricted Stock Units, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.